Clinical Trial Update: A Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

View source ↗

Summary

This completed study assessed the safety and effectiveness of rivaroxaban (Xarelto) for prevention of stroke and systemic embolism in Indian patients with non-v…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-valvular Atrial Fibrillation

Drugs mentioned

• Xarelto (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Non-valvular Atrial Fibrillation (NVAF) | Status: COMPLETED